Endo International PLC  

(Public, NASDAQ:ENDP)   Watch this stock  
Find more results for ENDP
+0.21 (0.33%)
Real-time:   12:11PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 63.73 - 64.58
52 week 40.24 - 82.16
Open 64.29
Vol / Avg. 297,877.00/1.61M
Mkt cap 9.86B
P/E     -
Div/yield     -
EPS -9.08
Shares 153.46M
Beta 1.20
Inst. own 97%
Jul 31, 2014
Q2 2014 Endo International PLC Earnings Release
Jul 31, 2014
Q2 2014 Endo International PLC Earnings Conference Call - Webcast
Jun 10, 2014
Endo Health Solutions Inc. Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 3.28% -20.46%
Operating margin 11.76% -14.77%
EBITD margin - 35.98%
Return on average assets 0.97% -8.15%
Return on average equity 3.38% -66.98%
Employees 3,371 -
CDP Score - -


25-28 North Wall Quay

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Endo International PLC, formerly Endo Health Solutions Inc., is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm , Opana ER, Voltaren Gel, Percocet , Frova , Supprelin LA, Vantas , Valstar and Fortesta Gel. The Company operates in three segments: Endo Pharmaceuticals, Qualitest and AMS. In April 2014, the Company acquired worldwide rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix, Inc. In July 2014, it acquired Grupo Farmaceutico Somar. In August 2014, Endo International PLC acquired DAVA Pharmaceuticals, Inc., a privately-held company specializing in generic pharmaceuticals.